Hospital Minimally Invasive Surgery Utilization for Gastrointestinal Cancer
The aim of the study was to evaluate the impact of receiving care at high minimally invasive surgery (MIS)-utilizing hospitalsBackground:
MIS techniques are used across surgical specialties. The extent of MIS utilization for gastrointestinal (GI) cancer resection and impact of receiving care at high utilizing hospitals is unclear.Methods:
This is a retrospective cohort study of 137,581 surgically resected esophageal, gastric, pancreatic, hepatobiliary, colon, and rectal cancer patients within the National Cancer Data Base (2010–2013). Disease-specific, hospital-level, reliability-adjusted MIS utilization rates were calculated to evaluate perioperative outcomes. Among patients for whom adjuvant chemotherapy (AC) was indicated, the association between days to AC and hospital MIS utilization was examined using generalized estimating equations. Association with risk of death was evaluated using multivariable Cox regression.Results:
Disease-specific MIS use increased significantly [42.0%–68.3% increase; trend test, P < 0.001 for all except hepatobiliary (P = 0.007)] over time. Most hospitals [range—30.3% (colon); 92.9% (pancreatic)] were low utilizers (≤30% of cases). Higher MIS utilization is associated with increased lymph nodes examined (P < 0.001, all) and shorter length of stay (P < 0.001, all). Each 10% increase in MIS utilization is associated with fewer days to AC [3.3 (95% confidence interval, 1.2–5.3) for MIS gastric; 3.3 ([0.7–5.8) for open gastric; 1.1 (0.3–2.0) days for open colon]. An association between MIS utilization and risk of death was observed for colon [Q2—hazard ratio (HR) 0.96 (0.89–1.02); Q3—HR 0.91 (0.86–0.98); Q4—HR 0.87 (0.82–0.93)] and rectal cancer [Q2—HR 0.89 (0.76–1.05); Q3—HR 0.84 (0.82–0.97); Q4—HR 0.86 (0.74–0.98)].Conclusions:
Most hospitals treating GI malignancies are low MIS utilizers. Our findings may reflect real-world MIS effectiveness for oncologic resection and could be useful for identifying hospitals with infrastructure and/or processes beneficial for multimodality cancer care.